Skip to content
The Policy VaultThe Policy Vault

Xalkori (crizotinib)Medica

Anaplastic Large Cell Lymphoma (ALK-positive)

Initial criteria

  • age ≥ 1 year
  • disease is anaplastic lymphoma kinase (ALK)-positive
  • EITHER medication is used for palliative-intent therapy OR patient has relapsed or refractory disease

Approval duration

1 year